Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | MMP10 | P09238 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL28793870 | 0.87 | DRD2 (0.42) | DRD2SLC6A4SLC6A3SLC6A2MMP3 | |
| SCHEMBL20267107 | 0.84 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2CCR1MEN1 | |
| SCHEMBL2274564 | 0.81 | TACR1 (0.53) | DRD2SLC6A2MEN1KMT2ATACR1 | |
| Hydrochloric Acid SCHEMBL4807753 | 0.80 | TACR1 (0.52) | DRD2SLC6A2MEN1KMT2ATACR1 | |
| SCHEMBL22817125 | 0.79 | SLC6A4 (0.65) | DRD2SLC6A4SLC6A3SLC6A2EPHX1 | |
| SCHEMBL14438093 | 0.78 | ALDH1A1 (0.50) | DRD2SLC6A4SLC6A3SLC6A2MMP9 | |
| SCHEMBL19627311 | 0.78 | SLC6A4 (0.52) | SLC6A4SLC6A3SLC6A2MMP3MMP1 | |
| SCHEMBL654668 | 0.77 | DRD2 (0.59) | DRD2CCR1MEN1KMT2A | |
| SCHEMBL653874 | 0.77 | DRD2 (0.59) | DRD2SLC6A3MMP3MMP9MMP8 | |
| SCHEMBL3892761 | 0.77 | DRD2 (0.54) | DRD2SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334927-A1 | Nitroimidazole Compound, Preparation Method Therefor And Use Thereof In Drug Manufacturing | SHANGHAI SUN-SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170334927-A1 | Nitroimidazole Compound, Preparation Method Therefor And Use Thereof In Drug Manufacturing | SHANGHAI SUN-SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| CN-105732659-A | Nitroimidazole compound, preparation method and pharmaceutical application thereof | 上海阳帆医药科技有限公司 | 2016-07-06 | — | — | CN | disclosed |
| US-20070254877-A1 | Indole Derivative and Use for Treatment of Cancer | TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254877-A1 | Indole Derivative and Use for Treatment of Cancer | TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254877-A1 | Indole Derivative and Use for Treatment of Cancer | TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1761539-A1 | INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER | Takeda Pharmaceutical Company Limited (JP) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005118587-A1 | INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334927-A1 | Nitroimidazole Compound, Preparation Method Therefor And Use Thereof In Drug Manufacturing | NISCH, CYP51A1, CYP4F11 | DRD2 2619/4885SLC6A4 1270/4885SLC6A3 2114/4885 |
| US-20070254877-A1 | Indole Derivative and Use for Treatment of Cancer | IGF1R, KDR, ERBB2 | DRD2 1084/4885SLC6A4 1124/4885SLC6A3 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.